- 1 Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in
- 2 cardiopulmonary phenotype Long COVID
- 3 Durstenfeld et al. CPET Findings >1 year after COVID-19
- 4 Matthew S. Durstenfeld^{1,2}, Michael J. Peluso^{1,3}, Punita Kaveti^{1,4}, Christopher Hill⁵, Danny Li²,
- 5 Erica Sander⁴, Shreya Swaminathan², Victor M. Arechiga², Scott Lu³, Sarah A Goldberg⁶,
- 6 Rebecca Hoh², Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos J. Petropoulos,
- J. Daniel Kelly^{6,8,9}, David V. Glidden⁶, Timothy J. Henrich¹⁰, Jeffrey N. Martin⁶, Yoo Jin Lee¹¹,
- 8 Mandar A. Aras^{1,4}, Carlin S. Long^{1,4}, Donald J. Grandis^{1,4}, Steven G. Deeks^{1,3}, Priscilla Y.
- 9 $Hsue^{1,2}$
- 10 1 Department of Medicine, University of California, San Francisco, CA, USA
- 2 Division of Cardiology, Zuckerberg San Francisco General, San Francisco, CA, USA
- 3 Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General
- 13 Hospital, University of California, San Francisco, USA
- 14 4 Division of Cardiology, UCSF Health
- 5 School of Medicine, University of California, San Francisco, USA
- 16 6 Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
- 17 TabCorp-Monogram Biosciences Inc, South San Francisco, CA USA
- 8 Institute of Global Health Sciences, University of California, San Francisco, USA
- 19 9 F.I. Proctor Foundation, University of California, San Francisco, USA
- 20 10 Division of Experimental Medicine, University of California, San Francisco, USA
- 21 11 Cardiac and Pulmonary Imaging, Department of Radiology, University of California, San
- 22 Francisco
- 23 Presented in part as a late breaking oral presentation at Conference on Retroviruses and
- Opportunistic Infections, 2/2022, as an oral presentation at the Heart Rhythm Society in 5/2022,
- and in full at the American Heart Association Scientific Sessions 11/2022.
- 26 Keywords: post-acute sequelae of COVID-19 (PASC); Long COVID; chronotropic
- 27 incompetence; cardiopulmonary exercise testing (CPET); inflammation
- 28 Word Count: 3736
- 29 Corresponding author:
- 30 Matthew S. Durstenfeld, MD MAS
- 31 Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital
- 32 1001 Potrero Avenue, 5G8
- 33 San Francisco, CA 94110, USA
- 34 Tel: +1 628 206 5562; Fax: +1 628 206 5447
- e-mail: matthew.durstenfeld@ucsf.edu
- 36 twitter: @durstenfeld
- 37 **Key Points:** Long COVID symptoms were associated with reduced exercise capacity on
- 38 cardiopulmonary exercise testing more than 1 year after SARS-CoV-2 infection. The most
- 39 common abnormal finding was chronotropic incompetence. Reduced exercise capacity was
- 40 associated with early elevations in inflammatory markers.

Abstract


1

34

- 2 BACKGROUND Mechanisms underlying persistent cardiopulmonary symptoms following
- 3 SARS-CoV-2 infection (post-acute sequelae of COVID-19 "PASC" or "Long COVID") remain
- 4 unclear. This study sought to elucidate mechanisms of cardiopulmonary symptoms and reduced
- 5 exercise capacity using advanced cardiac testing.
- 6 **METHODS** We performed cardiopulmonary exercise testing (CPET), cardiac magnetic
- 7 resonance imaging (CMR) and ambulatory rhythm monitoring among adults > 1 year after
- 8 confirmed SARS-CoV-2 infection in Long-Term Impact of Infection with Novel Coronavirus
- 9 cohort (LIINC; substudy of NCT04362150). Adults who completed a research echocardiogram
- 10 (at a median 6 months after SARS-CoV-2 infection) without evidence of heart failure or
- pulmonary hypertension were asked to complete additional cardiopulmonary testing
- approximately 1 year later. Although participants were recruited as a prospective cohort, to
- account for selection bias, the primary analyses were as a case-control study comparing those
- with and without persistent cardiopulmonary symptoms. We also correlated findings with
- previously measured biomarkers. We used logistic regression and linear regression models to
- adjust for potential confounders including age, sex, body mass index, time since SARS-CoV-2
- infection, and hospitalization for acute SARS-CoV-2 infection, with sensitivity analyses
- adjusting for medical history.
- 19 **RESULTS** Sixty participants (unselected for symptoms, median age 53, 42% female, 87% non-
- 20 hospitalized) were studied at median 17.6 months following SARS-CoV-2 infection. On
- 21 maximal CPET, 18/37 (49%) with symptoms had reduced exercise capacity (peak VO₂<85%
- predicted) compared to 3/19 (16%) without symptoms (p=0.02). The adjusted peak VO₂ was 5.2
- 23 ml/kg/min (95%CI 2.1-8.3; p=0.001) or 16.9% lower actual compared to predicted (95%CI 4.3-
- 24 29.6; p=0.02) among those with symptoms compared to those without symptoms. Chronotropic
- incompetence was present among 12/21 (57%) with reduced VO₂ including 11/37 (30%) with
- symptoms and 1/19 (5%) without (p=0.04). Inflammatory markers (hsCRP, IL-6, TNF- α) and
- 27 SARS-CoV-2 antibody levels measured early in PASC were negatively correlated with peak
- 28 VO₂ more than 1 year later. Late-gadolinium enhancement on CMR and arrhythmias on
- ambulatory monitoring were not present.
- 30 **CONCLUSIONS** We found evidence of objectively reduced exercise capacity among those
- with cardiopulmonary symptoms more than 1 year following COVID-19, which was associated
- 32 with elevated inflammatory markers early in PASC. Chronotropic incompetence may explain
- exercise intolerance among some with cardiopulmonary phenotype Long COVID.


1 Graphical Abstract

2



Cardiopulmonary Exercise Testing at Median 18 Months

< 85% Predicted: 18/37 (49%) 3/19 (16%) Peak VO₂ (ml/kg/min): 22.7 ± 8.1 29.6 ± 7.0



4

Most common abnormal exercise pattern: **chronotropic incompetence**, not ventilatory, cardiac, or deconditioning



Exercise capacity correlated with earlier inflammatory biomarkers



No evidence of myocarditis or arrhythmias

- 1 Abbreviations list: PASC=post-acute sequelae of COVID-19; hsCRP=high sensitivity c-
- 2 reactive protein; LIINC=Long-term Impact of Infection with Novel Coronavirus; LV=left
- 3 ventricle; RV=right ventricle; CPET=cardiopulmonary exercise testing; CMR=cardiac magnetic
- 4 resonance imaging; AHRR=adjusted heart rate reserve; POTS=postural orthostatic tachycardia
- 5 syndrome;

Background

1

22

2 Following acute SARS-CoV-2 infection, some individuals experience persistent symptoms of 3 "Long COVID" (LC), a type of post-acute sequelae of COVID-19 (PASC) [1]. By 3-6 months 4 after SARS-CoV-2 infection, cardiac function is generally normal on echocardiogram [2-4], suggesting that other techniques are needed to identify physiologic correlates of symptoms. 5 6 Cardiac magnetic resonance imaging (CMR) has revealed changes in parametric mapping and 7 late gadolinium enhancement (LGE) suggestive of cardiac inflammation without consistent 8 associations with symptoms or differences from controls [5-9]. Cardiopulmonary exercise testing 9 (CPET) has demonstrated reduced exercise capacity 3-6 months after SARS-CoV-2 infection without consistent patterns of limitations [10], and with limited data beyond 1 year after 10 infection. 11 We designed the Long-Term Impact of Infection with Novel Coronavirus (LIINC) study (NCT 12 04362150) to evaluate physical and mental health following SARS-COV-2 infection by 13 including individuals representing the spectrum of acute illness and post-acute-recovery [11]. 14 The purpose of this substudy was to elucidate mechanisms underlying cardiopulmonary 15 symptoms >1 year following SARS-CoV-2 infection by comparing symptomatic and recovered 16 individuals using CMR, CPET, and ambulatory rhythm monitoring, and correlating findings with 17 blood-based markers. 18 19 Methods As previously reported, LIINC is a San Francisco-based post-COVID cohort [11]. After our 20 initial echocardiogram-based study did not reveal cardiac mechanisms of symptoms [2], we 21

amended our protocol to conduct a second visit about 1 year later among participants who

1 completed an echocardiogram visit and were willing to undergo additional cardiopulmonary

testing. In this subset, we performed cross-sectional cardiopulmonary testing including CPET,

CMR, and ambulatory rhythm monitoring and correlated with already measured biomarkers from

prior cohort visits (including at the time of the echocardiogram for troponin, NT-pro-BNP, and

hsCRP).

2

3

4

5

6

8

9

10

11

12

14

15

18

19

20

21

22

Participants

7 We invited LIINC participants with PCR-confirmed SARS-CoV-2 infection who completed an

echocardiogram study visit to participate in additional cardiopulmonary testing irrespective of

symptom status. Those with pregnancy (due to expected changes during pregnancy), cardiac

disease (congenital heart disease, heart failure, myocardial infarction, coronary revascularization

with percutaneous coronary intervention or coronary artery bypass graft surgery, or other heart

surgery), pulmonary disease requiring home oxygen or lung surgery, and musculoskeletal or

13 neurologic conditions that precluded participation in cycler ergometry were excluded.

Additionally, those with non-MRI compatible implants or claustrophobia were excluded from

CMR; those with eGFR <30 ml/min/1.73m² were excluded from gadolinium.

16 *Symptoms*

17 Participants completed a structured interview about medical history, characteristics of acute

infection, cardiopulmonary diagnoses, and symptoms within the previous two weeks. We defined

cardiopulmonary symptoms as chest pain, dyspnea, or palpitations and symptoms as

cardiopulmonary symptoms or fatigue in the 2 weeks preceding the study visit. Consistent with

the WHO definition, all classified as symptomatic were >3 months after SARS-CoV-2 infection

with new symptoms without alternative cardiopulmonary explanations [12].

Blood-Based Markers

1

3

10

14

16

17

18

19

20

21

2 Participants had venous blood collected and processed for serum and plasma on the day of the

echocardiogram. Samples were batch processed for measurement of high-sensitivity troponin I,

4 N-terminal prohormone b-type natriuretic protein. A subset had antibodies and additional

5 markers measured at two earlier time points (<90 days and 90-150 days after infection) including

6 IL-6, IL-10, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), monocyte

7 chemoattractant protein-1 (MCP-1), interferon gamma (IFN - γ), and tumor necrosis factor

8 (TNF), and SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin G (IgG). These

9 samples were assayed by Monogram Biosciences using the Quanterix Simoa® platform blinded

with respect to patient and clinical information, and assay performance was consistent with

manufacturers' specifications [13].

12 Cardiac Magnetic Resonance Imaging

13 Multiparametric, sequence-standardized, blinded (technician and reader) cardiac magnetic

resonance imaging (CMR) was performed with a 3T system (Premier, General Electric),

including assessment of LV and RV size and function, parametric mapping, and late gadolinium

enhancement. Measurements were performed by a single reader at a dedicated workstation using

Medis (Leiden, Netherlands) and AI-assisted Arterys (San Francisco, CA) under supervision of a

senior cardiac imager, both blinded to clinical variables, and in accordance with Society for

Cardiovascular Magnetic Resonance recommendations. The full protocol is described in

Supplemental Methods.

Cardiopulmonary Exercise Testing

- 1 Noninvasive CPETs were performed by an exercise physiologist and cardiology nurse
- 2 practitioner blinded to participant data according to standard protocol using a metabolic cart
- 3 (Medical Graphics Corporation Ultima CardiO₂) and cycle ergometer (Lode Corival CPET) with
- 4 continuous 12 lead ECG monitoring (GE CASE) and noninvasive blood pressure and pulse
- 5 oximetry measurement. After rest ECG, BP and spirometry measurements were taken,
- 6 participants exercised to symptom limited maximal exertional with work increased in 1-minute
- 7 steps targeting a 10-minute test. We determined the work increase per 1 minute step based on the
- 8 expected peak VO₂ from the maximum voluntary ventilation for a goal 10 minute test, rounded
- 9 to 5 Watts/min increments based on reported exercise (range 10-30 Watts/min) in accordance
- with guidelines [14]. The full protocol is described in Supplemental Methods.
- We evaluated measured peak VO₂ (in ml/kg/min), estimated percent predicted peak VO₂ using
- the Wasserman equations [15], and classified peak VO₂ <85% predicted as reduced. We defined
- chronotropic incompetence as peak VO₂ <85% predicted, adjusted heart rate reserve (AHRR)
- 14 <80% [(HR_{peak}-HR_{rest})/(220-age-HR_{rest})], and no alternative explanation for exercise limitation
- 15 [16]. CPETs were interpreted independently by two cardiologists with discrepancies resolved
- through consensus.
- 17 Ambulatory Rhythm Monitoring
- An ambulatory rhythm monitor (Carnation Ambulatory Monitor, BardyDx) was placed on
- 19 participants' chests. They were instructed wear it for 2 weeks, press the button for symptoms,
- and record a symptom diary. Monitors were processed according to BardyDx standard
- 21 procedures, and reports were overread by a cardiologist.
- 22 Statistical Analysis

To compare participants with and without symptoms, we used logistic regression to estimate 1 adjusted odds ratios of parameters with symptoms and linear regression to estimate adjusted 2 mean differences. Adjusted models included age, sex, time since SARS-CoV-2 infection, 3 hospitalization, and body mass index. Non-normally distributed variables were log-transformed 4 and findings are reported per doubling or 10-fold change. For biomarker data we report 5 6 unadjusted Pearson's rho correlation coefficients and adjusted linear regression models. For 7 longitudinal data we used mixed effects models with random intercept per patient. We conducted 8 sensitivity analyses considering other symptom definitions and additionally adjusting for 9 potentially relevant medical history (hypertension, diabetes, asthma/COPD, and HIV) and echocardiographic (LV ejection fraction and LV diastolic function) and spirometry parameters 10 (forced vital capacity, forced expiratory volume in 1 second, and maximal voluntary ventilation. 11 12 REDCap was used for data entry. Statistical analyses were performed using STATA version 17.1. P values < 0.05 were considered statistically significant and were not adjusted for multiple 13 14 testing. The first author (MSD) had full access to the data and takes responsibility for the integrity of the data and analysis. The study was approved by the UCSF Institutional Review 15 Board (IRB 20-33000). All participants provided written informed consent prior to participation. 16 17 **Results** 18 Participant Characteristics 19 60 participants were included. Median age was 53 (IQR 41-59.5), 25 (42%) were female, and 8 20 21 (13%) were hospitalized during acute infection (Table 1). Median infection was in June 2020 (IQR March 2020-November 2020), so most participants were infected with the ancestral strain. 22

- 1 Four participants were vaccinated pre-infection ("breakthrough" infections), and 57 (95%)
- 2 received at least one SARS-CoV-2 vaccine prior to advanced testing.
- 3 Symptoms Persist at 18 Months
- 4 At visit 1 (median 6 months after infection; echocardiogram visit), 40/60 (67%) reported
- 5 symptoms and 32/60 (53%) reported cardiopulmonary symptoms. At visit 2 (median 17.6
- 6 months; advanced cardiopulmonary testing visit), 38/60 (63%) reported symptoms and 31/60
- 7 (52%) reported cardiopulmonary symptoms. Trajectories of individual symptoms were similar
- 8 (Supplemental Table 1). Self-reported reduced exercise capacity was highly associated with
- 9 symptoms: 29/33 (88%) reporting reduced exercise capacity also reported other symptoms
- versus 9/27 (33%) reporting preserved or improved exercise capacity (OR 14.5, 95%CI 3.9-54.1;
- 11 p<0.001).
- 12 CPETs were Maximal Tests
- Out of 60 participants who attended a CPET visit, 59 completed CPET at a median 17.6 months
- after infection (IQR 15.8-19.4); one participant was too hypertensive to undergo CPET. Out of
- 15 59 CPETs performed, one was excluded due to β-blocker use, two were excluded for
- submaximal tests with respiratory exchange ratio (RER) <1.05, leaving 56 CPETs for analysis.
- 17 Three were stopped for hypertensive response (after reaching >100% predicted peak VO₂); all
- others were symptom-limited maximal tests. No included participants were taking chronotropic
- medications or antianginals including β -blockers, non-dihydropyridine calcium channel blockers,
- 20 ivabradine, or long-acting nitrates at the time of CPET.
- 21 Exercise Capacity Lower than Predicted and Objectively Reduced Among those with Symptoms

- 1 Peak VO₂ was <85% predicted among 18/37 (49%) with symptoms compared to 3/19 (16%)
- 2 without symptoms (p=0.02). A 5 ml/kg/min decrease in peak VO₂ was associated with 2.75
- 3 times higher odds of symptoms (95%CI 1.39-5.44; p=0.004). Those with symptoms completed
- 4 less work despite higher perceived effort and similar respiratory exchange ratio (Table 2).
- 5 Despite reduced exercise capacity among those with symptoms, most CPET parameters were not
- 6 associated with symptoms (Table 2 and Supplemental Table 2 for additional parameters
- 7 including rest spirometry & echocardiographic parameters).
- 8 As shown in Figure 1 and Table 2, peak VO₂ was 22.7±8.1 and 29.6±7.0 ml/kg/min among those
- 9 with and without symptoms, respectively, a difference of 6.9 ml/kg/min (95%CI 2.5-11.3;
- p=0.003) and 92% versus 107% percent predicted (difference 15% predicted, 95%CI; p=0.02).
- The adjusted difference in peak VO₂ was 5.2 ml/kg/min (95%CI 2.1-8.3; p=0.001), 0.4 L/min
- 12 (95%CI 0.09 to 0.73; p=0.02), and 16.9% lower predicted (95%CI 4.3-29.6; p=0.02). Results
- were unchanged in sensitivity analysis adding diabetes and hypertension; the adjusted difference
- in peak VO₂ was 4.5 ml/kg/min (95%CI 1.40-7.50; p=0.005). Similarly, results were unchanged
- in sensitivity analyses accounting for diabetes, hypertension, asthma/COPD, and HIV, resting
- spirometry values, and echocardiographic parameters (adjusted difference 3.9 ml/kg/min, 95%CI
- 17 0.6-7.3; p=0.02), but did vary based on symptom classification used (Supplemental Table 3).
- 18 Classification of Reduced Exercise Capacity by Pattern of CPET Findings
- 19 Among 56 maximal CPETs, 21 (37%) had peak VO₂<85% predicted; no participants had
- 20 ventilatory limitation, 3 had cardiac limitation, and one had a hypertensive response. Four had
- 21 findings most consistent with deconditioning/obesity, and one participant's peak VO₂ was 84%
- predicted with no other abnormalities (possibly deconditioning). Twelve (21% overall, 57% of
- 23 those with reduced exercise capacity) had chronotropic incompetence. Among those with

- symptoms, 11/37 (30%) had chronotropic incompetence compared to 1/19 (5%) without
- 2 symptoms (p=0.04).
- Compared to those with peak $VO_2 \ge 85\%$ without an impaired chronotropic response, those with
- 4 chronotropic incompetence had 49 bpm lower peak heart rate (119 bpm vs 170; 95%CI 40-60;
- 5 p<0.0001; Figure 2). They completed 100 Watts less work (196 vs 96, 95%CI 49-152; p=0.0005)
- and had 12.2 ml/kg/min lower peak VO₂ (95%CI 6.5-17.9; p=0.0001). Those with chronotropic
- 7 incompetence also had reduced HR recovery at 1 minute (7.9 bpm lower, 95%CI 1.3-14.6;
- 8 p=0.02). In absolute terms, those with chronotropic incompetence generated a mean peak oxygen
- 9 consumption of 1.59 L/min compared to 2.35 L/min among those with normal exercise capacity
- 10 (difference 0.76 L/min, 95%CI 0.23 to 1.28; p=0.007); a linear regression model with only rest
- and peak heart rate explains 54% of the difference in relative oxygen consumption (ml/kg/min)
- and 34% of the difference in absolute oxygen consumption (L/min).
- 13 Normal Cardiac Structure and Function on CMR
- 14 Forty-three participants completed CMR, including two without gadolinium (one eGFR<30 and
- one due to inability to place an IV). CMR demonstrated normal LV and RV volumes and
- ejection fraction, and only RV volumes were associated with symptoms with smaller RV size
- associated with higher odds of symptoms (Table 3). No participants had LGE suggestive of
- myocardial scar, and native T1 and T2 parametric mapping values and ECV were not associated
- with symptoms. Some participants (10/43, 23%) had trace or small pericardial effusions with no
- 20 difference by symptoms (p=0.59).
- 21 Palpitations are Not Explained by Arrhythmias on Ambulatory Rhythm Monitoring

- 1 Of those included, 38 participants were and returned an ambulatory rhythm monitor. Lower
- 2 maximum heart rate, age-predicted maximum heart rate, and adjusted heart rate reserve were all
- 3 associated with symptoms consistent with our CPET findings (Table 4). One symptomatic
- 4 individual had a single episode of non-sustained ventricular tachycardia without recorded
- 5 symptoms or button push; no other clinically significant arrhythmias including atrial fibrillation
- 6 or atrial flutter were present in either group (Supplemental Table 4). The burden of sinus
- 7 tachycardia and supraventricular tachycardias was not significantly increased among those with
- 8 symptoms. Premature ventricular contractions were associated with symptoms, and we could not
- 9 exclude an association between premature atrial contractions and symptoms (Table 4).
- Symptomatic individuals pressed the button 3.2 times more often (95%CI 2.1-4.7; p<0.001).
- Button pushes were mostly during sinus rhythm, sinus tachycardia, or supraventricular ectopy
- 12 (Supplemental Figure). Results were similar considering only those with palpitations.
- 13 Ambulatory Rhythm Monitoring Correlates of Chronotropic Incompetence on CPET
- 14 CPET peak HR correlated with maximum sinus HR during ambulatory monitoring (Pearson's
- r=0.71; p<0.001), with ambulatory peak HR 29 bpm lower among those with chronotropic
- incompetence (95%CI 13-45; p<0.001). Chronotropic incompetence was associated with 12.6
- bpm higher minimum HR (95%CI 3-22; p=0.01) and 59ms lower HR variability by standard
- deviation n-to-n (95%CI 24-95; p=0.002; Supplemental Table 4). PR intervals were not
- significantly longer among those with chronotropic incompetence (171ms vs 168ms; p=0.72).
- 20 One symptomatic individual had 2nd degree Mobitz type 1 (normal finding), and no participants
- 21 had 2nd degree Mobitz type 2 or 3rd degree heart block.
- 22 Markers of Inflammation Early in PASC are Associated with Exercise Capacity and Pericardial
- 23 Effusions More than 1 Year Later

- 1 Markers of inflammation in the blood (hsCRP, IL-6, TNF) and SARS-CoV-2 RBD IgG level,
- 2 but not hs-troponin or NT-pro-BNP measured at 3-9 months after infection are negatively
- 3 correlated with peak VO₂ more than one year after infection (Figure 3). After adjustment, peak
- 4 VO₂ was 6.2 ml/kg/min lower per doubling of TNF (95%CI 0.6-11.8; p=0.03) and 1.8 ml/kg/min
- 5 lower per doubling of hsCRP (95%CI 0.8-2.9; p=0.001).
- 6 Longitudinal serum biomarkers of inflammation, neurologic injury, and SARS-CoV-2 RBD IgG
- 7 were measured at <90 days from SARS-CoV-2 acute infection (median 52 days) and between
- 8 90-150 days (median 124 days) in 36 participants who underwent CPET (Figure 4), all prior to
- 9 vaccination. SARS-CoV-2 IgG (2.99-fold higher mean ratio, 95%CI 1.41-6.33; p=0.004) and
- TNF (1.34-fold higher mean ratio, 95%CI 1.11-1.61; p=0.002) were higher at <90 days among
- those with reduced exercise capacity. At 90-150 days, only SARS-CoV-2 IgG (2.12-fold higher
- mean ratio, 95%CI 1.02-4.43; p=0.04) remained statistically significant, although after
- adjustment it was no longer statistically significant (1.1 ml/kg/min per doubling, 95%CI -0.3 to
- 2.4; p=0.11). We could not exclude an effect of IL-6 (1.34-fold higher mean ratio, 95%CI 0.92-
- 1.96; p=0.11; adjusted 2.1 ml/kg/min per doubling, 95%CI -0.5-4.6; p=0.11). Except for IL-6, all
- other biomarkers decreased over time regardless of eventual exercise capacity.

Discussion

- We demonstrate that clinically meaningful reductions in objective exercise capacity are
- associated with LC symptoms more than 1 year after SARS-CoV-2 infection. Our findings
- 20 suggest that chronotropic incompetence contributes to exercise limitations in LC. We found
- 21 elevated inflammatory markers and SARS-CoV-2 antibody levels early in PASC are associated
- 22 with reduced exercise capacity more than a year later. We did not find evidence of myocarditis,
- cardiac dysfunction, or clinically significant arrhythmias. Finally, our study validates that CPET

- 1 allows objective measurement of patient-reported exercise intolerance and therefore may be
- 2 useful for interventional trials of therapeutics for LC.
- 3 Connections between Inflammation, Reduced Exercise Capacity, and Autonomic Responses
- 4 Our study extends prior findings that inflammatory markers including hsCRP, IL-6, and TNF are
- 5 negatively correlated with peak VO₂ early after COVID-19 hospitalization [17] to >1 year after
- 6 infection and those not hospitalized. This correlation may reflect a common cause for
- 7 inflammation and exercise limitations in PASC (i.e., viral persistence [18], immune activation
- 8 [19]), or these markers could be on the causal path from infection to symptoms and reduced
- 9 exercise capacity. Endothelial and coronary microvascular dysfunction occur in PASC [20-23]
- and are associated with chronotropic incompetence and inflammation [24, 25]. Inflammation
- may alter autonomic function which could explain reduced exercise capacity and chronotropic
- incompetence.
- Data from animal models support the hypothesis that chronotropy may be related to
- inflammatory signals and endothelial functions. Apart from COVID-19, IL-6 impairs
- chronotropic responses to autonomic signaling in mice [26] and may regulate energy allocation
- during exercise [27]. In addition, IL-6 and TNF impair endothelial function in animal models via
- increasing oxidative stress and suppressing endothelial nitric oxide synthase pathways [28].
- 18 Ideally, clinical trials should evaluate whether anti-inflammatory strategies improve chronotropy
- 19 and endothelial function, as both impact exercise capacity and risk of cardiovascular disease.
- 20 Autonomic Function, Sinus Node Function, and Inflammation in PASC
- 21 Altered autonomic function is a possible unifying explanation for our and others' CPET findings
- in PASC including altered peripheral oxygen extraction [29], preload failure [30-32], and

- disordered breathing [30]. Orthostatic intolerance, an autonomic symptom, occurs in PASC [33],
- 2 and skin biopsies suggest small fiber neuropathy in LC-associated postural-orthostatic
- 3 tachycardia syndrome [34, 35]. Effects on brainstem regulatory regions or the amygdala [36]
- 4 could also modify autonomic responses to exercise.
- 5 An alternative hypothesis is that SARS-CoV-2 could alter sinus node function. Autopsy studied
- 6 have not specifically examined sinus node tissue for evidence of persistent viral infection of the
- 7 sinus node [37], but hamster models suggest that SARS-CoV-2 can infect hamster sinoatrial
- 8 node cells and *in vitro* sinoatrial-like pacemaker cells resulting in altered calcium handling,
- 9 activated inflammatory pathways, and induced ferroptosis [38]. Sinus node remodeling may
- reduce sinus node reserve in heart failure [39]. Although we did not find evidence of cardiac
- 11 fibrosis or sinus node dysfunction, we cannot fully exclude that sinus node dysfunction may
- contribute to CI. A combination of autopsy studies that specifically examine sinoatrial tissue and
- clinical studies may be necessary to identify the relevant mechanisms.
- 14 Inflammation modifies autonomic and chronotropic responses. Young adults recovering from
- SARS-CoV-2 have elevated sympathetic activation at rest [40]. Chronic inflammation in other
- settings is associated with parasympathetic and sympathetic imbalance, chronotropic
- incompetence and reduced exercise capacity [24, 41]. Thus, chronic inflammation could blunt
- 18 chronotropy in PASC even without autonomic nervous system or sinus node damage.
- 19 Other Studies of PASC using CPET
- Our study is consistent with others that have reported lower peak VO₂ among those with PASC
- 21 compared to recovered individuals mostly at 3-6 months after severe COVID-19, which we
- 22 summarized in a systematic review and meta-analysis [10]. Our findings build upon earlier

studies by (1) demonstrating reduced peak VO₂ and chronotropic incompetence much later after 1 infection (2) including evaluation of cardiac inflammation, structural heart disease and 2 3 arrhythmias, (3) adjusting for confounders, (4) including recovered persons as comparators, and (5) demonstrating associations with longitudinal biomarkers. 4 Differences in classification of exercise limitations across CPET studies of PASC may arise from 5 6 selection bias, confounding, different CPET protocols, and different interpretation algorithms. 7 Deconditioning, which contributes to reduced exercise capacity after any illness, may be 8 misidentified from noninvasive CPET, and has been commonly reported 3-6 months after 9 hospitalization [10]. Although reductions in physical activity after COVID-19 [42] suggest deconditioning contributes, our findings argue against deconditioning as the only explanation for 10 most individuals as deconditioning more commonly demonstrates an accelerated rather than a 11 blunted heart rate response. 12 Five other studies have also found that chronotropic incompetence contributes to exercise 13 limitations in PASC [32, 42-45]. Chronotropic incompetence may be underestimated in some 14 studies as sensitivity and specificity vary with exercise modality and protocol and including sub-15 16 maximal tests or patients on beta-blockers reduces specificity. Diagnosing chronotropic incompetence may have prognostic implications: it is associated with incident cardiovascular 17 disease, sudden death, and all-cause mortality among men without coronary artery disease [46-18 19 48]. 20 Impaired peripheral oxygen extraction, best assessed with invasive CPET, may also contribute to 21 exercise limitations in PASC [29], perhaps via changes in autonomic regulation of 22 microcirculatory function [49] or altered metabolism [50]. We did not find differences in VO₂/work slope, a noninvasive correlate of measured oxygen extraction. Although not observed 23

- among our participants, dysfunctional (rapid, erratic) breathing and exercise hyperventilation
- 2 may contribute to dyspnea in PASC [30, 51, 52].
- 4 CMR and Ambulatory Rhythm Monitoring Findings
- 5 CMR findings suggestive of myocarditis without cardiac dysfunction may be present in the early
- 6 post-acute period [5, 8, 53]. Consistent with studies at later time points [6, 7], we did not find
- 7 evidence of abnormal function or LGE, suggesting that myocarditis is unlikely to explain
- 8 symptoms in most with PASC.

- 9 Our findings are consistent with two studies that did not find arrhythmias in early PASC [54, 55].
- In contrast to a study in early PASC [56], inappropriate sinus tachycardia was present only in
- one individual (without symptoms). Therefore, arrhythmias and inappropriate sinus tachycardia
- are unlikely to explain symptoms among most individuals with PASC.
- 13 *Implications for Therapy*
- 14 Investigation into mechanisms of PASC may benefit from proof-of-concept approaches to
- identify potential therapies. Although vaccination reduces the risk of PASC [57, 58] and the
- newer circulating variants may be associated with lower risk of Long COVID [59], there is no
- data regarding whether anti-viral, anti-inflammatory, or anti-coagulant strategies improve
- 18 exercise capacity in PASC. In chronotropic incompetence separate from COVID-19, chronic
- supervised exercise is the only intervention demonstrated to improve exercise capacity and
- surrogates of autonomic function [60-62]. Exercise is an effective treatment for postural
- 21 orthostatic tachycardia syndrome, which may also be related to post-viral alterations in
- 22 autonomic responses to stress and occurs in PASC [63, 64]. Reports of post-exertional malaise or

symptom exacerbation (PEM/PESE) in PASC overlapping with ME/CFS [65-67] mean exercise-

based interventions should be considered with caution. A study of a six-week structured pacing

intervention improved physical activity levels and reduced PESE [68], and another study found

that supervised exercise may be helpful rather than harmful in PASC [69].

Limitations

2

3

4

5

7

8

9

10

11

12

13

14

15

16

17

18

19

21

22

6 The main limitations of this observational study arise from the small sample size, non-

probabilistic sampling, and cross-sectional cardiac measures. Secondly, the difference in peak

VO₂ was sensitive to the case definition, but our definition is consistent with current consensus

definitions [12]. Volunteer bias may result in overestimated prevalence and magnitude of

reduced exercise capacity but should not affect classification of limitations. We did not include

an uninfected comparator group and nearly all individuals were unvaccinated at the time of

initial SARS-CoV-2 infection. Although we excluded those with cardiac disease, adjusted for

measured confounders, and conducted sensitivity analyses adjusting for additional confounders,

unmeasured residual confounders including pre-COVID fitness remain. Adjustment (in BMI, for

example) may not have fully accounted for confounding. Misclassification of exercise limitations

could occur since we did not perform invasive CPET, stress echocardiography, stress CMR, or

stress ventriculography. Lastly, we lacked contemporaneous biomarker data with CPETs to

ascertain whether a transient inflammatory process or ongoing inflammation is more likely.

Conclusions

In conclusion, more than 1 year after pre-vaccine index SARS-CoV-2 infection, reduced exercise

capacity on CPET is associated with LC symptoms, chronotropic incompetence, and higher

inflammatory markers and antibody levels in the early post-acute period, but not evidence of

- 1 myocarditis or arrhythmias. Further investigation into mechanisms of cardiopulmonary PASC
- 2 should include evaluation of inflammatory pathways, chronotropic function, and the autonomic
- 3 nervous system to identify therapeutic targets.

Acknowledgements: We would like to thank the research participants and the members of the 1 LIINC study team. We would like to thank Dr. Kara Lynch and Dr. Alan Wu for their assistance 2 3 with measuring cardiac biomarkers and hsCRP. We would also like to acknowledge support from Jeremy Lambert from Quanterix (Billerica, MA) and Patrick Kaiser from BardyDx, a 4 division of Hillrom (Bellevue, Washington). We acknowledge the contributions of the UCSF 5 6 Clinical and Translational Science Unit. 7 This study was funded by philanthropic gifts from Charles W. Swanson and the Ed and Pearl 8 Fein Foundation, research grants from the NIH/NLBI including L30 HL159695 and K12 9 HL143961, and internal funds from the Division of Cardiology at Zuckerberg San Francisco General. This work was assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS 10 Research Institute. MSD is supported by K12HL143961. MJP is supported by K23AI157875. 11 JDK is supported by NIH/NIAID K23AI135037. TJH is supported by NIH/NIAID 12 13 3R01A1141003-03S1. PYH is supported by NIH/NAID 2K24AI112393-06. This publication 14 was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the 15 responsibility of the authors and do not necessarily represent the official views of the NIH. The 16 17 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 18 **Author Contributions:** 19 20 MSD designed the study, obtained IRB approval, acquired data, analyzed data, interpreted the 21 findings, and wrote the first draft of the manuscript. MJP assisted in study design, participant 22 recruitment, data interpretation, and critical revision of the manuscript. PK and YJL conducted CMR measurements, drafted the MRI methods, and contributed to interpretation of the MRI 23

findings. CH led the ambulatory rhythm monitoring measurements and participated in 1 interpretation of the findings. DL and ES participated in the cardiopulmonary exercise testing 2 measurements, drafting of the CPET methods, CPET interpretation, and provided input on the 3 manuscript. SS and VMA participated in measurements, data management, and revisions of the 4 5 manuscript. DVG participated in statistical design, analysis and visualization. SL, SAG, and RH 6 participated in participant recruitment, measurement, and data management. AC, BCY, JWW, and CJP participated in biomarker measurement and provided input on drafts of the manuscript. 7 JDK, TJH, and JNM participated in the study design, interpretation of results, and revision of the 8 9 manuscript. CSL and DJG provided funding and participated in designing the study, interpreting results, and revising the manuscript. SGD and PYH provided funding, oversight, and mentorship 10 for the first two authors and participated in study design, interpretation of results, and critical 11 manuscript revision. 12 Competing Interests statement: AC, BCY, JWW, and CJP are employees of Monogram 13 Biosciences, Inc., a division of LabCorp. PYH has received modest honoraria from Gilead and 14 Merck and research grant from Novartis unrelated to the submitted work. All other authors report 15 no other competing interests. 16

1 Tables:

6

2 Table 1: Baseline Characteristics (n=60)

		Symptoms (n=38)	No Symptoms (n=22)
Months since Infection, median (IQR)		17.7 (15.9, 19.4)	17.5 (15.8, 18.6)
Age (years), media	Age (years), median (IQR)		54.5 (42, 61)
Sex	Male	19 (50%)	16 (73%)
	Female	19 (50%)	6 (27%)
Race/ Ethnicity	Hispanic/Latino	10 (24%)	5 (22%)
	White	26 (63%)	15 (65%)
	Black/African American	2 (5%)	1 (4%)
	Asian	2 (9%)	3 (7%)
BMI (kg/m ²), mean	n±SD	30.2±7.5	28.1±5.0
Change in BMI from visit 1 to visit 2, mean±SD		1.18 ± 1.4	1.32 ± 2.1
BMI Category	24.9 or less	10 (26%)	7 (32%)
	25 to 29.9	11 (29%)	10 (45%)
	30 to 34.5	9 (24%)	4 (18%)
	35 or greater	8 (21%)	1 (5%)
Medical History	Hypertension	9 (24%)	5 (24%)
	Diabetes	6 (16%)	1 (5%)
	Asthma/COPD	10 (27%)	2 (10%)
	HIV	10 (26%)	6 (27%)
	Autoimmune Disease	3 (8%)	1 (5%)
	Cancer	1 (3%)	1 (5%)
	Kidney Disease	1 (3%)	0 (0%)
TT 1: 1: 1	Former or Current Tobacco use	13 (34%)	3 (14%)
Hospitalized (including ICU)		6 (16%)	2 (9%)
ICU		2 (33% hospitalized)	0

Table 1 Legend: Demographic information, past medical history, and severity of acute COVID-19 by

⁴ hospitalization/ICU status of the participants who underwent advanced cardiopulmonary testing. Abbreviations:

⁵ BMI=body mass index, ICU=intensive care unit, IQR=Interquartile Range

1 Table 2: Selected Cardiopulmonary Exercise Testing Parameters by Symptom Status (n=56)

	Measure	Symptoms (n=37)	No Symptoms (n=19)	Adjusted OR (95%CI; p value)	Adjusted Difference (95%CI; p value)
Exercise Capacity	Peak VO ₂ , ml/kg/min	22.7 ± 8.1	29.6 ± 7.0	2.75 per -5 ml/kg/min (1.39- 5.44; p=0.004)	-5.2 (-8.3to -2.1; p=0.001)
	Peak VO2, % predicted	92.0 ± 22.0	107.3 ± 22.0	1.22 per -5% (1.04- 1.43; p=0.01)	-17 (-30 to -4.3; p=0.01)
	Peak VO2, L/min	1.9 ± 0.6	2.4 ± 0.7	1.18 per -0.1/min (1.03-1.37; p=0.02)	-0.41 (-0.73 to -0.09; p=0.01)
	Proportion <85% predicted	18 (49%)	3 (16%)	7.97 (1.56 to 40.8; p=0.01)	
Ventila- tory	Peak Respiratory Rate	37.5 ± 8.7	40.8 ± 9.7	0.95 (0.88-1.02; p=0.17)	-3.8 (-10.0 to 2.4; p=0.23)
	Breathing Reserve (MVV-V _{Emax})	44.5 (38.3, 59.0)	32.8 (24.0, 44.8)	1.04 (1.00-1.07; p=0.05)	14.8 (0.7 to 29; p=0.04)
	Vent. Efficiency (V _E /VCO ₂ slope) ^a	27.5 ± 3.7	25.8 ± 3.7	1.18 (0.98-1.44; p=0.09)	2.0 (-0.4 to 4.4; p=0.10)
Peripheral	VO ₂ to Work slope	9.9±3.0	10.9±3.5	0.94 (0.76-1.17; p=0.60)	-0.5 (-2.6 to 1.5; p=0.60)
Cardiac	VO ₂ pulse, ml/beat	13.1 ± 3.3	15.4 ± 4.5	0.85 (0.69-1.03; p=0.11)	-1.6 (-3.8 to 0.5; p=0.13)
	SBP peak, mm Hg	173.9 ± 31.7	189.2 ± 23.3	0.86 per 5 mm Hg (0.73-1.03; p=0.10)	-13.2 (-31.3 to 4.8; p=0.15)
	Rest, bpm	78.3 ± 14.5	75.2 ± 10.4	1.01 (0.96-1.06; p=0.75)	0.9 (-6.9 to 8.7; p=0.83)
Heart Rate	Peak, bpm	147.2 ± 25.7	154.1 ± 21.7	0.97 (0.94-1.01; p = 0.10)	-9.3 (-21 to 2; p=0.11)
	Peak, % Age Predicted	86.2 ± 11.9	94.1 ± 9.3	0.92 (0.85-0.99; p=0.02)	-8.5 (-15.2 to -1.8; p=0.02)
	Adjusted HR Reserve Achieved, %	73.6 ± 22.0	84.9 ± 21.2	0.97 (0.94-1.00; p=0.05)	-12.1 (-24.6 to 0.5; p=0.06)
	HR Recovery at 1 min, bpm	14.4 ± 7.4	14.0 ± 10.0	1.04 (0.95-1.14; p=0.39)	2.0 (-2.9 to 6.9; p=0.42)
Exertion	Work (Watts)	140.8 ± 60.6	196.2 ± 68.2	1.20 per -10 Watts (1.04 to 1.40; p=0.01)	-49.6 (-86.2 to -13.0; p=0.009)
	Perceived Exertion, Borg Scale 6-20 ^b	16.2 ± 1.8	14.9 ± 2.2	1.64 (1.05-2.57; p=0.03)	1.3 (0.1 to 2.6; p=0.03)
	Peak Respiratory Exchange Ratio (VCO ₂ /VO ₂)	1.18 (1.12, 1.23)	1.20 (1.12, 1.30)	1.01 per -0.1 (0.48- 2.12; p=0.98)	0.03 (-0.09 to 0.02; p=0.23)

- 1 Table 2 Legend: We present both the odds ratios for the association between CPET parameters and symptoms
- 2 estimated using logistic regression with adjustment for age, sex, time since COVID, hospitalization for acute
- 3 COVID, BMI category and the estimated adjusted mean differences between those with and without symptoms
- 4 using linear regression adjusting for the same covariates. Sensitivity analysis incorporating history of hypertension,
- 5 diabetes, and lung disease had no substantive changes in effect sizes or confidence intervals. aVE/VCO2 slope could
- 6 not be determined for one participant without symptoms. ^bBorg scale of perceived exertion was assessed every 2
- 7 minutes; these represent the last measurement prior to test stopping. **Bold text represents p<0.05.** Abbreviations:
- 8 AT=Anaerobic threshold; bpm=beats per minute; FVC=Forced Vital Capacity; HR=heart rate; DBP=diastolic blood
- 9 pressure; MVV=maximal voluntary ventilation; SBP=systolic blood pressure; V_D/V_T =Dead space ratio; V_E = minute
- ventilation; VCO₂=carbon dioxide production; pVO₂=peak oxygen consumption (VO₂); Vent=Ventilatory.

1 Table 3. Cardiac Magnetic Resonance Imaging Parameters (n=41) by Symptom Status

Meaning	Parameter	Symptoms (n=25)	No Symptoms (n=18)	Adjusted OR (95%CI; p value)
Months since SARS-CoV-2 Infection, mean±SD		15.9±3.8	15.9±3.9	
Hematocrit, mean±SD		43.0 ± 3.5	44.5 ± 4.1	0.86 (0.67 to 1.09; p=0.21)
Body Surface Area, m ²		1.95 ± 0.22	1.90 ± 0.16	1.26 per 0.1 m ² (0.74-2.17; p=0.38)
Left	LVEDi, ml/m ²	63.6 ± 13.9	69.3 ± 12.3	0.97 (0.91-1.03; p=0.27)
Ventricular	LVESi, ml/m ²	24.4 ± 6.9	25.3 ± 7.0	1.00 (0.89-1.12; p=0.97)
Size and	LVEF, %	61.8 ± 5.9	63.3 ± 5.8	0.93 (0.82-1.05; p=0.26)
Function	LV Mass Index, gm/m ²	47.6 ± 7.9	51.6 ± 7.6	0.98 (0.90 to 1.06; p=0.60)
	Stroke Volume, ml ^a	77.2 ± 18.1	84.2 ± 18.1	0.97 (0.93-1.01; p=0.20)
Right	RVEDi, ml/m ²	65.3 ± 13.5	75.6 ± 12.4	0.92 (0.86 to 0.99; p=0.02)
Ventricular	RVESi, ml/m ²	27.1 ± 6.4	31.3 ± 7.6	0.86 (0.75=0.99; p=0.04)
Size and Function	RVEF, %	58.9 ± 5.0	58.4 ± 5.0	0.75 (0.86 to 1.14; p=0.93)
Markers of	T1 Native	1202 (1141,	1219 (1153,	1.00 (0.99-1.00; p=0.51)
Cardiac	Mapping, ms	1253)	1248)	
Inflammation	Post-Contrast T1 Mapping Time, ms	603 (507, 634)	624 (577, 655)	1.00 (0.99 to 1.01; p=0.64)
	Extracellular Volume, %	26.7 ± 6.3	24.2 ± 5.3	1.08 (0.92-1.26; p=0.35)
	T2 Native Mapping, ms	46.5 (44.4, 51.0)	48.0 (44.0, 51.4)	0.97 (0.83-1.13; p=0.70)
Cardiac Fibrosis	LGE	0	0	
Possible	Pericardial	6 (24%)	5 (22%)	0.47 (0.08-2.71; p=0.41)
Pericardial Inflammation	Effusion			

Table 3 Legend: CMR parameters by cardiopulmonary symptoms given as mean±SD or median (intraquartile range) for non-normally distributed variables. Logistic regression was used to estimated odds of having symptoms for a given change in each parameter adjusted for age, sex, BMI category, hospitalization, and time since infection. Only RV end diastolic and end systolic volume indices were associated with symptoms with larger RV size associated with lower odds of symptoms. Bold text represents p<0.05. Abbreviations: LVEDi=Left ventricular end diastolic volume indexed to body surface area; LVESi=Left ventricular end diastolic volume indexed to body surface area; RVEF=left ventricular end diastolic volume indexed to body surface area; RVESi=Right ventricular end diastolic volume indexed to body surface area; RVEF=Right ventricular Ejection Fraction. LGE=Late Gadolinium Enhancement. aLV stroke volumes are reported but there is a high correlation between LV and RV stroke volumes (Pearson's r=0.96).

1 Table 4: Ambulatory Rhythm Monitoring Findings by Symptoms (n=38)

Parameter	Symptoms (n=24)	No Symptoms (n=14)	Adjusted OR for symptoms (95%CI; p value)	Adjusted OR for palpitations (95%CI; p value)
Monitoring Time, days	4 (3, 13)	8 (3, 13)		
Average Heart Rate, bpm	77.5 ± 11.4	74.4 ± 4.5	1.04 (0.96 to 1.14; p=0.34)	1.11 (0.98-1.28; p=0.11)
Minimum HR, bpm	50.2 ± 12.5	44.9 ± 2.8	1.13 (0.96-1.33; p=0.13)	1.38 (1.04-1.82; p=0.02)
Maximum HR, bpm	142.2 ± 19.0	157.4 ± 21.4	1.77 per -10 (1.03 to 3.03; p=0.04)	2.60 (1.07-6.34; p=0.04)
Maximum HR, % predicted	85.1 ± 9.1	94.9 ± 11.3	3.39 per -10 (1.09 to 10.6; p=0.04)	9.15 (1.14-72.9; p=0.04)
Adjusted HRR achieved, %	70.7 ± 19.7	89.9 ± 20.1	1.77 per -10 (1.09 to 2.89; p=0.02)	4.20 (1.34-13.2; p=0.01)
Heart Rate Variability, SDNN	143.5 (113.3, 185.5)	155.7 (137.0, 177.0)	1.00 per -10 (0.87 to 1.16; p=0.97)	1.91 (1.08-3.60; p=0.03)
PAC, % burden	0.02 (0.01, 0.10)	0.01 (0.01, 0.04)	1.36 per 10-fold increase (0.58 to 3.20; p=0.48)	1.05 (0.36-3.05; p=0.93)
PVC, % burden	0.01 (0.01, 0.15)	0.01 (0, 0.01)	2.74 per 10-fold increase (1.14 to 6.53; p=0.02)	2.20 (0.92-5.31; p=0.08)
Sinus tachycardia, % burden	7 (3, 13)	4 (3, 6)	1.15 (0.97 to 1.37; p=0.12)	1.20 (1.00-1.43; p =0.05)
Episodes of SVT* per week	1.2 (0, 3.5)	0 (0, 3)	1.08 (0.91 to 1.28; p =0.39)	1.15 (0.91-1.46; p=0.25)
Episodes of Nonsustained VT	0	1		
Button Pushes	2.5 (0.5,7)	1 (0, 2)	1.33 (1.00-1.76; p=0.05)	1.13 (0.93-1.36; p=0.22)

Table 4 Legend. Values are reported as mean±SD or median (interquartile range) for non-normally distributed variables assessed by histogram. Those with self-reported symptoms pressed the symptom button on the monitor more 3.2 times more often (95%CI 2.1-4.7; p<0.001). **Bolded results are p<0.05.**

2 3

4

5

Figures:

1

2

Figure 1. Exercise Capacity by Symptoms and HR Response to Exercise (n=56)





Figure 1 Legend: Box and whisker plots of peak VO₂ (ml/kg/min in Panel A and percent 4 predicted in Panel B) among those without (blue) and with symptoms (pink) 17.6 months after 5 6 SARS-CoV-2 infection (top). In Panel C peak VO₂ in ml/kg/min is plotted by adjusted heart rate reserve (AHRR) to demonstrate the cluster of symptomatic individuals with low peak VO₂ and 7 chronotropic incompetence in the bottom left. Panel D demonstrates CPET patterns among those 8 with Long COVID symptoms: half achieved greater than 85% predicted peak VO₂, and 9 10 chronotropic incompetence was the most common pattern among those with reduced exercise capacity. 11

Figure 2. Heart Rate during Exercise by Chronotropic Response to Exercise

1



3 Figure 2 Legend: Mean heart rate is plotted as a function of exercise time normalized to percent

- 4 of predicted peak VO₂: in purple are those with normal exercise capacity (peak VO₂ >85%
- 5 predicted and normal heart rate response (n=16), in teal are those with normal exercise capacity
- 6 (peak VO2>85%; n=8) and blunted heart rate response (AHRR<80%; n=8), and in yellow are
- 7 those with chronotropic incompetence (n=9), as described in Supplemental Table 4.

Figure 3. Correlations between Peak VO2 and Previously Measured Biomarkers




Figure 3 Legend. Scatterplots and linear trend lines of peak VO₂ (measured at ~18 months) by natural log of previously measured biomarker levels with unadjusted Pearson's rho correlations and p-values listed (top row, median 6 months after SARS-CoV-2 infection; bottom two rows median 3.5 months after SARS-CoV-2 infection). Prior hsCRP, IL-6, TNF and SARS-CoV-2 receptor binding domain antibody levels were correlated with subsequent peak VO₂. All antibody levels were measured prior to vaccination.


Figure 4. Change in Biomarkers Early Post-Infection by Eventual Exercise Capacity at 18

2 months (n=35)

1

3

4



those with reduced exercise capacity (red) and preserved exercise capacity (blue) measured at <90 days from SARS-CoV-2 acute infection (median 52 days from symptom onset) and between

Figure 4 Legend: Mean \pm standard error of the mean for serum biomarkers over time among

- 7 90-150 days (median 124 days from symptom onset) in 35 participants who underwent CPET.
- 8 Inflammatory markers decreased over time, except for IL-6 among those with reduced exercise
- 9 capacity. MCP-1, TNF, and IgG were higher early among those with reduced exercise capacity.
- 10 TNF and IgG remained higher and GFAP became lower among those with reduced exercise
- 11 capacity at the second time point.

References

- 2 1. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms
- 3 after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-61.
- 4 Epub 2022/08/08. doi: 10.1016/s0140-6736(22)01214-4. PubMed PMID: 35934007; PubMed Central
- 5 PMCID: PMCPMC9352274.
- 6 2. Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. Role of antibodies,
- 7 inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after
- 8 SARS-CoV-2 infection. JCI Insight. 2022;7(10). Epub 2022/04/08. doi: 10.1172/jci.insight.157053.
- 9 PubMed PMID: 35389890; PubMed Central PMCID: PMCPMC9220849.
- 10 3. Fayol A, Livrozet M, Boutouyrie P, Khettab H, Betton M, Tea V, et al. Cardiac performance in
- patients hospitalized with COVID-19: a 6 month follow-up study. ESC Heart Fail. 2021;8(3):2232-9. Epub
- 12 2021/03/28. doi: 10.1002/ehf2.13315. PubMed PMID: 33773099; PubMed Central PMCID:
- 13 PMCPMC8120370.
- 14 4. Tangen J, Aukrust P, Barratt-Due A, Skulstad H, Edvardsen T. Reduced Cardiac Function by
- 15 Echocardiography in a Minority of COVID-19 Patients >3 Months after Hospitalization. Journal of the
- 16 American Society of Echocardiography. 2022;35(2):243-4. doi: 10.1016/j.echo.2021.10.014.
- 17 5. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of
- 18 Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease
- 19 2019 (COVID-19). JAMA Cardiology. 2020. doi: 10.1001/jamacardio.2020.3557.
- 20 6. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, et al. Prospective Case-Control Study of
- 21 Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. JACC:
- 22 Cardiovascular Imaging. 2021;14(11):2155-66. doi: doi:10.1016/j.jcmg.2021.04.011.
- 23 7. Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M, et al. Symptom
- 24 Persistence Despite Improvement in Cardiopulmonary Health Insights from longitudinal CMR, CPET and
- lung function testing post-COVID-19. EClinicalMedicine. 2021;41:101159. Epub 2021/10/26. doi:
- 26 10.1016/j.eclinm.2021.101159. PubMed PMID: 34693230; PubMed Central PMCID: PMCPMC8527025.
- 27 8. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of
- 28 myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic
- 29 resonance. Eur Heart J. 2021;42(19):1866-78. Epub 2021/02/18. doi: 10.1093/eurheartj/ehab075.
- 30 PubMed PMID: 33596594; PubMed Central PMCID: PMCPMC7928984.
- 31 9. Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu E, et al. Long-term
- 32 cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022;28(10):2117-23. Epub
- 33 2022/09/06. doi: 10.1038/s41591-022-02000-0. PubMed PMID: 36064600; PubMed Central PMCID:
- 34 PMCPMC9556300.
- 35 10. Durstenfeld MS, Sun K, Tahir P, Peluso MJ, Deeks SG, Aras MA, et al. Use of Cardiopulmonary
- 36 Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults: A Systematic Review and Meta-
- 37 analysis. JAMA Netw Open. 2022;5(10):e2236057. Epub 2022/10/13. doi:
- 38 10.1001/jamanetworkopen.2022.36057. PubMed PMID: 36223120.
- 39 11. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Persistence, Magnitude,
- 40 and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection:
- Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases. 2021;9(2). doi:
- 42 10.1093/ofid/ofab640.
- 43 12. Soriano JM, J; Diaz, JV; Murthy, S;; Relan, P. A clinical case definition of post COVID-19 condition
- by a Delphi consensus. In: Organization WH, editor. 2021.1 ed: ; 2021.
- 45 13. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of Immune
- 46 Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory

- 1 Syndrome Coronavirus 2 Infection. J Infect Dis. 2021;224(11):1839-48. Epub 2021/10/23. doi:
- 2 10.1093/infdis/jiab490. PubMed PMID: 34677601; PubMed Central PMCID: PMCPMC8643408.
- 3 14. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to
- 4 cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association.
- 5 Circulation. 2010;122(2):191-225. Epub 2010/06/30. doi: 10.1161/CIR.0b013e3181e52e69. PubMed
- 6 PMID: 20585013.
- 7 15. Wasserman K HJ, Sue DY, Stringer W, Whipp BJ. Principles of Exercise Testing and Interpretation.
- 8 4th ed. Philadelpha: Lippincott Williams and Wilkins; 2005.
- 9 16. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and
- 10 management. Circulation. 2011;123(9):1010-20. Epub 2011/03/09. doi:
- 11 10.1161/CIRCULATIONAHA.110.940577. PubMed PMID: 21382903; PubMed Central PMCID:
- 12 PMCPMC3065291.
- 13 17. Ribeiro Baptista B, d'Humieres T, Schlemmer F, Bendib I, Justeau G, Al-Assaad L, et al.
- 14 Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-
- month follow-up of prospective COVulnerability cohort. Respir Res. 2022;23(1):68. Epub 2022/03/24.
- doi: 10.1186/s12931-022-01977-z. PubMed PMID: 35317815; PubMed Central PMCID:
- 17 PMCPMC8938727.
- 18 18. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating SARS-CoV-2
- spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022. Epub 2022/09/03. doi:
- 20 10.1093/cid/ciac722. PubMed PMID: 36052466.
- 21 19. Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-CoV-2-specific
- 22 T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of
- 23 SARS-CoV-2. PLoS Pathog. 2022;18(5):e1010359. Epub 2022/05/27. doi: 10.1371/journal.ppat.1010359.
- 24 PubMed PMID: 35617421.
- 25 20. Paneroni M, Pasini E, Vitacca M, Scalvini S, Comini L, Pedrinolla A, et al. Altered Vascular
- 26 Endothelium-Dependent Responsiveness in Frail Elderly Patients Recovering from COVID-19 Pneumonia:
- 27 Preliminary Evidence. J Clin Med. 2021;10(12). Epub 2021/07/03. doi: 10.3390/jcm10122558. PubMed
- 28 PMID: 34207876; PubMed Central PMCID: PMCPMC8228458.
- 29 21. Mejia-Renteria H, Travieso A, Sagir A, Martínez-Gómez E, Carrascosa-Granada A, Toya T, et al.
- 30 In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19. International Journal of
- 31 Cardiology. 2021;345:153-5. doi: https://doi.org/10.1016/j.ijcard.2021.10.140.
- 32 22. Drakos S, Chatzantonis G, Bietenbeck M, Evers G, Schulze AB, Mohr M, et al. A cardiovascular
- 33 magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19
- 34 patients. Sci Rep. 2021;11(1):15667. Epub 2021/08/04. doi: 10.1038/s41598-021-95277-z. PubMed
- 35 PMID: 34341436; PubMed Central PMCID: PMCPMC8329060.
- 36 23. Ahmed Al, Saad JM, Han YS, Malahfji M, Nabi F, Mahmarian JJ, et al. Coronary Microvascular
- 37 Health in Patients with Prior Covid-19 Infection: Implications for Long-Covid Syndrome. Journal of the
- 38 American College of Cardiology. 2022;79(9):1822-. doi: doi:10.1016/j.jcmg.2022.07.006. PubMed PMID:
- 39 WOS:000781026602023.
- 40 24. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA, et al. Comparison of endothelial vasodilator
- 41 function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without
- 42 chronotropic incompetence to exercise test. Heart. 2006;92(5):609-14. Epub 2005/09/15. doi:
- 43 10.1136/hrt.2005.064147. PubMed PMID: 16159987; PubMed Central PMCID: PMCPMC1860951.
- 44 25. Bechsgaard DF, Hove JD, Suhrs HE, Bové KB, Shahriari P, Gustafsson I, et al. Women with
- 45 coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise
- 46 capacity. International Journal of Cardiology. 2019;293:1-9. doi:
- 47 https://doi.org/10.1016/j.ijcard.2019.07.048.

- 1 26. Hajiasgharzadeh K, Mirnajafi-Zadeh J, Mani AR. Interleukin-6 impairs chronotropic
- 2 responsiveness to cholinergic stimulation and decreases heart rate variability in mice. Eur J Pharmacol.
- 3 2011;673(1-3):70-7. Epub 2011/11/03. doi: 10.1016/j.ejphar.2011.10.013. PubMed PMID: 22044916.
- 4 27. Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue.
- 5 Nat Metab. 2022;4(2):170-9. Epub 2022/02/26. doi: 10.1038/s42255-022-00538-4. PubMed PMID:
- 6 35210610.
- 7 28. Lee J, Lee S, Zhang H, Hill MA, Zhang C, Park Y. Interaction of IL-6 and TNF-α contributes to
- 8 endothelial dysfunction in type 2 diabetic mouse hearts. PLoS One. 2017;12(11):e0187189. Epub
- 9 2017/11/03. doi: 10.1371/journal.pone.0187189. PubMed PMID: 29095915; PubMed Central PMCID:
- 10 PMCPMC5667841.
- 11 29. Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, et al. Persistent
- 12 Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest.
- 13 2022;161(1):54-63. Epub 2021/08/15. doi: 10.1016/j.chest.2021.08.010. PubMed PMID: 34389297;
- 14 PubMed Central PMCID: PMCPMC8354807.
- 15 30. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of Cardiopulmonary
- 16 Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease. JACC Heart Fail.
- 17 2021;9(12):927-37. Epub 2021/12/04. doi: 10.1016/j.jchf.2021.10.002. PubMed PMID: 34857177;
- 18 PubMed Central PMCID: PMCPMC8629098.
- 19 31. Brown JT, Saigal A, Karia N, Patel RK, Razvi Y, Constantinou N, et al. Ongoing Exercise Intolerance
- 20 Following COVID-19: A Magnetic Resonance-Augmented Cardiopulmonary Exercise Test Study. J Am
- 21 Heart Assoc. 2022;11(9):e024207. Epub 2022/04/27. doi: 10.1161/JAHA.121.024207. PubMed PMID:
- 22 35470679.
- 32. Szekely Y, Lichter Y, Sadon S, Lupu L, Taieb P, Banai A, et al. Cardiorespiratory Abnormalities in
- Patients Recovering from Coronavirus Disease 2019. J Am Soc Echocardiogr. 2021;34(12):1273-84.e9.
- 25 Epub 2021/09/12. doi: 10.1016/j.echo.2021.08.022. PubMed PMID: 34508837; PubMed Central PMCID:
- 26 PMCPMC8425293.
- 27 33. Jamal SM, Landers DB, Hollenberg SM, Turi ZG, Glotzer TV, Tancredi J, et al. Prospective
- 28 Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19. Journal of the American
- 29 College of Cardiology. 2022;79(23):2325-30. doi: doi:10.1016/j.jacc.2022.03.357.
- 30 34. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem
- 31 Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367-79. Epub
- 32 2021/12/26. doi: 10.1002/ana.26286. PubMed PMID: 34952975.
- 33 35. Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, et al. Peripheral Neuropathy
- Evaluations of Patients With Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3).
- 35 Epub 2022/03/03. doi: 10.1212/nxi.000000000001146. PubMed PMID: 35232750; PubMed Central
- 36 PMCID: PMCPMC8889896.
- 36. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is
- associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707. Epub
- 39 2022/03/08. doi: 10.1038/s41586-022-04569-5. PubMed PMID: 35255491; PubMed Central PMCID:
- 40 PMCPMC9046077.
- 41 37. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and
- 42 persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758-63. Epub 2022/12/15.
- 43 doi: 10.1038/s41586-022-05542-y. PubMed PMID: 36517603; PubMed Central PMCID:
- 44 PMCPMC9749650.
- 45 38. Han Y, Zhu J, Yang L, Nilsson-Payant BE, Hurtado R, Lacko LA, et al. SARS-CoV-2 Infection Induces
- 46 Ferroptosis of Sinoatrial Node Pacemaker Cells. Circ Res. 2022;130(7):963-77. Epub 2022/03/09. doi:
- 47 10.1161/CIRCRESAHA.121.320518. PubMed PMID: 35255712; PubMed Central PMCID:
- 48 PMCPMC8963443.

- 1 39. Sanders P, Kistler PM, Morton JB, Spence SJ, Kalman JM. Remodeling of sinus node function in
- 2 patients with congestive heart failure: reduction in sinus node reserve. Circulation. 2004;110(8):897-
- 3 903. Epub 2004/08/11. doi: 10.1161/01.CIR.0000139336.69955.AB. PubMed PMID: 15302799.
- 4 40. Stute NL, Stickford JL, Province VM, Augenreich MA, Ratchford SM, Stickford ASL. COVID-19 is
- 5 getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from
- 6 SARS-CoV-2. J Physiol. 2021;599(18):4269-85. Epub 2021/06/27. doi: 10.1113/JP281888. PubMed PMID:
- 7 34174086; PubMed Central PMCID: PMCPMC8447023.
- 8 41. Franssen WMA, Keytsman C, Marinus N, Verboven K, Eijnde BO, van Ryckeghem L, et al.
- 9 Chronotropic incompetence is more frequent in obese adolescents and relates to systemic inflammation
- and exercise intolerance. J Sport Health Sci. 2021. Epub 2021/02/03. doi: 10.1016/j.jshs.2021.01.010.
- 11 PubMed PMID: 33529767.
- 12 42. Margalit I, Yelin D, Sagi M, Rahat MM, Sheena L, Mizrahi N, et al. Risk factors and
- multidimensional assessment of long COVID fatigue: a nested case-control study. Clin Infect Dis. 2022.
- 14 Epub 2022/04/12. doi: 10.1093/cid/ciac283. PubMed PMID: 35403679.
- 15 43. Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, Courel-Ibáñez J.
- 16 Chronotropic Incompetence in Non-Hospitalized Patients with Post-COVID-19 Syndrome. Journal of
- 17 Clinical Medicine. 2021;10(22):5434. PubMed PMID: doi:10.3390/jcm10225434.
- 18 44. Abdallah SJ, Voduc N, Corrales-Medina VF, McGuinty M, Pratt A, Chopra A, et al. Symptoms,
- 19 Pulmonary Function, and Functional Capacity Four Months after COVID-19. Ann Am Thorac Soc.
- 20 2021;18(11):1912-7. Epub 2021/04/20. doi: 10.1513/AnnalsATS.202012-1489RL. PubMed PMID:
- 21 33872135; PubMed Central PMCID: PMCPMC8641826.
- 45. Ladlow P, O'Sullivan O, Houston A, Barker-Davies R, May S, Mills D, et al. Dysautonomia
- 23 following COVID-19 is not associated with subjective limitations or symptoms but is associated with
- objective functional limitations. Heart Rhythm. 2022;19(4):613-20. doi:
- 25 https://doi.org/10.1016/j.hrthm.2021.12.005.
- 26 46. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile
- during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951-8. Epub 2005/05/13.
- 28 doi: 10.1056/NEJMoa043012. PubMed PMID: 15888695.
- 29 47. Savonen KP, Lakka TA, Laukkanen JA, Halonen PM, Rauramaa TH, Salonen JT, et al. Heart rate
- 30 response during exercise test and cardiovascular mortality in middle-aged men. European Heart Journal.
- 31 2006;27(5):582-8. doi: 10.1093/eurheartj/ehi708.
- 48. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired Chronotropic
- 33 Response to Exercise Stress Testing as a Predictor of Mortality. JAMA. 1999;281(6):524-9. doi:
- 34 10.1001/jama.281.6.524.
- 35 49. Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, et al. Insights
- 36 From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic
- 37 Fatigue Syndrome. Chest. 2021;160(2):642-51. Epub 2021/02/13. doi: 10.1016/j.chest.2021.01.082.
- 38 PubMed PMID: 33577778; PubMed Central PMCID: PMCPMC8727854.
- 39 50. de Boer E, Petrache I, Goldstein NM, Olin JT, Keith RC, Modena B, et al. Decreased Fatty Acid
- 40 Oxidation and Altered Lactate Production during Exercise in Patients with Post-acute COVID-19
- 41 Syndrome. Am J Respir Crit Care Med. 2022;205(1):126-9. Epub 2021/10/20. doi: 10.1164/rccm.202108-
- 42 1903LE. PubMed PMID: 34665688; PubMed Central PMCID: PMCPMC8865580.
- 43 51. Fresard I, Genecand L, Altarelli M, Gex G, Vremaroiu P, Vremaroiu-Coman A, et al. Dysfunctional
- 44 breathing diagnosed by cardiopulmonary exercise testing in 'long COVID' patients with persistent
- 45 dyspnoea. BMJ Open Respir Res. 2022;9(1):e001126. Epub 2022/04/01. doi: 10.1136/bmjresp-2021-
- 46 001126. PubMed PMID: 35354589; PubMed Central PMCID: PMCPMC8968537.
- 47 52. Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, et al. Hyperventilation as
- one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. Eur Respir J.

- 2021;58(2):2101578. Epub 2021/08/14. doi: 10.1183/13993003.01578-2021. PubMed PMID: 34385265;
- 2 PubMed Central PMCID: PMCPMC8361302 support from Servier, outside the submitted work. A. Cohen-
- 3 Solal has received grants or honoraria from Novartis, Servier, Daiichi Sankyo, Vifor, Menarini and
- 4 Cardiorentis, outside of the submitted work. J. Frija-Masson reports non-financial support from Vitalaire,
- 5 Boehringer Ingelheim, Oxyvie and LVL Medical, outside the submitted work. All other authors declare
- 6 that the research was conducted in the absence of any commercial or financial relationships that could
- 7 be construed as a potential conflict of interest.
- 8 53. Morrow AJ, Sykes R, McIntosh A, Kamdar A, Bagot C, Bayes HK, et al. A multisystem, cardio-renal
- 9 investigation of post-COVID-19 illness. Nat Med. 2022. Epub 2022/05/24. doi: 10.1038/s41591-022-
- 10 01837-9. PubMed PMID: 35606551.
- 11 54. Ingul CB, Grimsmo J, Mecinaj A, Trebinjac D, Berger Nossen M, Andrup S, et al. Cardiac
- 12 Dysfunction and Arrhythmias 3 Months After Hospitalization for COVID-19. J Am Heart Assoc.
- 13 2022;11(3):e023473. Epub 2022/01/21. doi: 10.1161/JAHA.121.023473. PubMed PMID: 35048715.
- 14 55. Dewland TA, Whitman IR, Win S, Sanchez JM, Olgin JE, Pletcher MJ, et al. Prospective arrhythmia
- surveillance after a COVID-19 diagnosis. Open Heart. 2022;9(1). Epub 2022/01/22. doi:
- 16 10.1136/openhrt-2021-001758. PubMed PMID: 35058344; PubMed Central PMCID: PMCPMC8783964.
- 17 56. Aranyó J, Bazan V, Lladós G, Dominguez MJ, Bisbal F, Massanella M, et al. Inappropriate sinus
- tachycardia in post-COVID-19 syndrome. Scientific Reports. 2022;12(1):298. doi: 10.1038/s41598-021-
- 19 03831-6.
- 20 57. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine.
- 21 2022. doi: 10.1038/s41591-022-01840-0.
- 22 58. Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, et al. Outcomes among confirmed
- 23 cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun.
- 24 2022;13(1):5663. Epub 2022/10/13. doi: 10.1038/s41467-022-33415-5. PubMed PMID: 36224173;
- 25 PubMed Central PMCID: PMCPMC9556711.
- 26 59. Durstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, et al. Factors Associated With
- 27 Long COVID Symptoms in an Online Cohort Study. Open Forum Infect Dis. 2023;10(2):ofad047. Epub
- 28 2023/02/28. doi: 10.1093/ofid/ofad047. PubMed PMID: 36846611; PubMed Central PMCID:
- 29 PMCPMC9945931.
- 30 60. Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ, et al. Effects of exercise
- training on chronotropic incompetence in patients with heart failure. Am Heart J. 1999;138(2 Pt 1):233-
- 32 40. Epub 1999/07/30. doi: 10.1016/s0002-8703(99)70106-7. PubMed PMID: 10426833.
- 33 61. Kiilavuori K, Toivonen L, Näveri H, Leinonen H. Reversal of autonomic derangements by physical
- training in chronic heart failure assessed by heart rate variability. Eur Heart J. 1995;16(4):490-5. Epub
- 35 1995/04/01. doi: 10.1093/oxfordjournals.eurheartj.a060941. PubMed PMID: 7671894.
- 36 62. Myers J, Hadley D, Oswald U, Bruner K, Kottman W, Hsu L, et al. Effects of exercise training on
- 37 heart rate recovery in patients with chronic heart failure. Am Heart J. 2007;153(6):1056-63. Epub
- 38 2007/06/02. doi: 10.1016/j.ahj.2007.02.038. PubMed PMID: 17540210.
- 39 63. Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci.
- 40 2018;215:20-7. Epub 2018/07/14. doi: 10.1016/j.autneu.2018.07.001. PubMed PMID: 30001836;
- 41 PubMed Central PMCID: PMCPMC6289756.
- 42 64. George SA, Bivens TB, Howden EJ, Saleem Y, Galbreath MM, Hendrickson D, et al. The
- 43 international POTS registry: Evaluating the efficacy of an exercise training intervention in a community
- 44 setting. Heart Rhythm. 2016;13(4):943-50. Epub 2015/12/23. doi: 10.1016/j.hrthm.2015.12.012.
- 45 PubMed PMID: 26690066.
- 46 65. Bonilla H, Quach TC, Tiwari A, Bonilla AE, Miglis M, Yang PC, et al. Myalgic
- 47 Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection
- 48 (PASC): Results from a post-COVID-19 multidisciplinary clinic. Front Neurol. 2023;14:1090747. Epub

- 1 2023/03/14. doi: 10.3389/fneur.2023.1090747. PubMed PMID: 36908615; PubMed Central PMCID:
- 2 PMCPMC9998690.

- 3 66. Jason LA, Dorri JA. ME/CFS and Post-Exertional Malaise among Patients with Long COVID. Neurol
- 4 Int. 2022;15(1):1-11. Epub 2023/01/18. doi: 10.3390/neurolint15010001. PubMed PMID: 36648965;
- 5 PubMed Central PMCID: PMCPMC9844405.
- 6 67. Vernon SD, Hartle M, Sullivan K, Bell J, Abbaszadeh S, Unutmaz D, et al. Post-exertional malaise
- 7 among people with long COVID compared to myalgic encephalomyelitis/chronic fatigue syndrome
- 8 (ME/CFS). Work. 2023. Epub 2023/03/14. doi: 10.3233/wor-220581. PubMed PMID: 36911963.
- 9 68. Parker M, Sawant HB, Flannery T, Tarrant R, Shardha J, Bannister R, et al. Effect of using a
- 10 structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal
- 11 cohort with the post-COVID-19 syndrome. J Med Virol. 2023;95(1):e28373. Epub 2022/12/04. doi:
- 12 10.1002/jmv.28373. PubMed PMID: 36461167; PubMed Central PMCID: PMCPMC9878088.
- 13 69. Jimeno-Almazán A, Buendía-Romero Á, Martínez-Cava A, Franco-López F, Sánchez-Alcaraz BJ,
- 14 Courel-Ibáñez J, et al. Effects of a concurrent training, respiratory muscle exercise, and self-management
- 15 recommendations on recovery from post-COVID-19 conditions: the RECOVE trial. Journal of Applied
- 16 Physiology. 2023;134(1):95-104. doi: 10.1152/japplphysiol.00489.2022. PubMed PMID: 36476156.